News & Updates

Patients with symptomatic peripheral artery disease and type 2 diabetes see notable improvements in their walking capacity and quality of life with once-weekly semaglutide injections in the phase 3b STRIDE study.

Data from the phase IV DUET* study presented at AAN 2025 reinforce the potential of low-sodium oxybate (LXB) for the treatment of narcolepsy or idiopathic hypersomnia (IH).

Combination treatment with esketamine plus either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is beneficial in treatment-resistant depression (TRD), with notable variations in outcomes depending on the choice of antidepressant class, as shown in a large retrospective study.

Vitiligo occurs as a cutaneous immune-related adverse event during immune checkpoint inhibitor (ICI) therapy in most melanoma and nonmelanoma cancer patients with partial or complete response to treatment, according to a systematic review.